ArticleBMC pulmonary medicine2025
The distribution and the clinical importance of MUC5B and TERT variants in Turkish patients with idiopathic pulmonary fibrosis.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe role of genetic variants in Mucin-5B (MUC5B) and telomerase reverse transcriptase (TERT) in idiopathic pulmonary fibrosis (IPF) pathogenesis, as well as their associations with clinical characteristics, remain uncertain and may exhibit ethnic variations.
methodsThis single-center, cross-sectional study aimed to investigate the distribution of MUC5B rs35705950 and TERT rs2736100 variants among Turkish IPF patients. Additionally, we assessed associations between these genetic variants and clinical parameters including gender-age-physiology (GAP) score, percent predicted forced vital capacity (FVC%), percent predicted diffusing capacity for carbon monoxide (DLCO%), and the presence of honeycombing on high-resolution computed tomography (HRCT).
resultsThe allele frequency of the TERT rs2736100 variant showed no significant difference between IPF patients and healthy controls (41.7% vs. 43.7%, OR = 0.92, p = 0.73). Conversely, the allele frequency of the MUC5B rs35705950 variant was significantly higher in IPF patients compared to controls (39.6% vs. 12%, OR = 4.81, p = 0.0001). IPF patients carrying the homozygous MUC5B variant (TT) exhibited significantly higher mean FVC% values than those without the variant (GG) (82.2% vs. 71.7%, respectively; p = 0.004). Furthermore, the mean age at diagnosis was significantly older in IPF patients carrying at least one T allele of the MUC5B variant (GT + TT) compared to non-carriers (GG) (67.7 years vs. 62.3 years, respectively; p = 0.013).
conclusionsOur findings indicate that the MUC5B rs35705950 variant is significantly associated with increased IPF susceptibility among Turkish patients. In contrast, the TERT rs2736100 variant was not linked to IPF risk. Additionally, the presence of the MUC5B rs35705950 variant correlated with later disease onset and relatively preserved pulmonary function in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.